Stock USCGONNASDAQHealthcareProfitless Growth

CG Oncology, Inc. Common stock(CGON) Stock Analysis | Healthcare

USD --+0.00%

Reward52Moderate

Risk24Low

75%Data

Revenue growing 1983% YoY

USD —+0.00 (+0.00%) Previous close · NASDAQ

Market cap 5.97Bn

Reward Ratingⓘ52 Moderate reward assessment · 75% data coverage

Bottom 50% of stocksView factors

Risk Ratingⓘ24 Low risk assessment

Risk factors availableUnlock details

Earnings & dividend markersEarnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is CG Oncology, Inc. Common stock?

, a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.

AI Brief Pro

The brief on CG Oncology, Inc. Common stock

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is CG Oncology, Inc. Common stock?

, a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 5.97B.